Cogent Communications Reports $29.8M Third-Quarter Loss
Story updates
11:58:04 AM UTC
SquawkNews
Cogent Communications 3Q Loss/Shr 62c >CCOI
Related stories
Monte Rosa Therapeutics Reports Third-Quarter 2026 Results and Business Updates
The company said positive GFORCE-1 Phase 1 results showed MRT-8102 reduced key pathogenic drivers of atherosclerotic disease.
M impact | EQUITY | Nov 05, 2026, 12:19 PM UTC
Tecnoglass Reports Third-Quarter 2026 Results
Tecnoglass reported record revenue of $310.6 million, up 19.2% year over year. The supplied body is truncated after “driven by Co.”
M impact | EQUITY | Nov 05, 2026, 12:17 PM UTC
Apyx Medical Reports Third-Quarter 2026 Revenue of $14.0 Million
Apyx Medical reported third-quarter 2026 revenue of $14.0 million, driven by 17% growth in the Sur
M impact | EQUITY | Nov 05, 2026, 12:15 PM UTC
Avalo Therapeutics Reports Third-Quarter 2026 Financial Results
The company also reported recent business updates, including work toward a registrational Phase 3 program for abdakibart in hidradenitis suppurativa.
M impact | EQUITY | Nov 05, 2026, 12:14 PM UTC
Ingredion Q3 Adjusted Earnings and Sales Fall
Ingredion reported lower Q3 adjusted earnings and sales. Shares were down before the bell.
M impact | EQUITY | Nov 05, 2026, 12:04 PM UTC
Cartesian Therapeutics Reports Third-Quarter 2026 Results and Business Update
The company said its Phase 3 AURORA trial of Descartes-08 in myasthenia gravis is advancing toward a data readout; the body text is truncated.
M impact | EQUITY | Nov 05, 2026, 12:04 PM UTC